Abstract
Semicarbazide-sensitive amine-oxidase (SSAO) is present in various human tissues and in plasma. Oxidative deamination of short-chain aliphatic amines is catalyzed by this enzyme to afford the corresponding aldehydes, ammonia and hydrogen peroxide. Methylamine and aminoacetone have been recognized to be physiological substrates for SSAO. There are several pathological states where increased serum SSAO activity have been found, such as diabetes mellitus, congestive heart failure, multiple types of cerebral infarction, uraemia, and hepatic cirrhosis. The role of SSAO in pathophysiology of diabetes has been most extensively investigated. The elevated formation of the potentially cytotoxic products of the enzyme may contribute to the endothelial injury of blood vessels, resulting in the early development of severe atherosclerosis; it may also contribute to the pathogenesis of diabetic angiopathy. It is now suggested that SSAO inhibitors may prevent the development of atherosclerosis and diabetic complications as well. Inhibitors can be conveniently subdivided into the main groups of hydrazine derivatives, arylalkylamines, propenyl- and propargylamines, oxazolidinones, and haloalkylamines. Of them, aryl(alkyl)hydrazines, and 3-halo-2-phenylallylamines are generally very strong SSAO inhibitors. Most of these inhibitors of SSAO have been originally developed for other purposes, or they are simple chemical reagents with highly reactive structural element(s); these compounds have not been able to fulfil all criteria of high potency, selectivity, and acceptable toxicity. New potent compounds with selectivity and low toxicity are needed, which may prove useful tools for understanding the roles and function of SSAO, or they may even be valuable substances for treatment of various diseases.
Keywords: semicarbazide-sensitive amine oxidase (ssao), diabetes, atherosclerosis, vap-1, inhibitors, hydrazines, haloallylamines, haloalkylamines
Current Medicinal Chemistry
Title: Semicarbazide-Sensitive Amine Oxidase: Current Status and Perspectives
Volume: 11 Issue: 10
Author(s): P. Matyus, B. Dajka-Halasz, A. Foldi, N. Haider, D. Barlocco and K. Magyar
Affiliation:
Keywords: semicarbazide-sensitive amine oxidase (ssao), diabetes, atherosclerosis, vap-1, inhibitors, hydrazines, haloallylamines, haloalkylamines
Abstract: Semicarbazide-sensitive amine-oxidase (SSAO) is present in various human tissues and in plasma. Oxidative deamination of short-chain aliphatic amines is catalyzed by this enzyme to afford the corresponding aldehydes, ammonia and hydrogen peroxide. Methylamine and aminoacetone have been recognized to be physiological substrates for SSAO. There are several pathological states where increased serum SSAO activity have been found, such as diabetes mellitus, congestive heart failure, multiple types of cerebral infarction, uraemia, and hepatic cirrhosis. The role of SSAO in pathophysiology of diabetes has been most extensively investigated. The elevated formation of the potentially cytotoxic products of the enzyme may contribute to the endothelial injury of blood vessels, resulting in the early development of severe atherosclerosis; it may also contribute to the pathogenesis of diabetic angiopathy. It is now suggested that SSAO inhibitors may prevent the development of atherosclerosis and diabetic complications as well. Inhibitors can be conveniently subdivided into the main groups of hydrazine derivatives, arylalkylamines, propenyl- and propargylamines, oxazolidinones, and haloalkylamines. Of them, aryl(alkyl)hydrazines, and 3-halo-2-phenylallylamines are generally very strong SSAO inhibitors. Most of these inhibitors of SSAO have been originally developed for other purposes, or they are simple chemical reagents with highly reactive structural element(s); these compounds have not been able to fulfil all criteria of high potency, selectivity, and acceptable toxicity. New potent compounds with selectivity and low toxicity are needed, which may prove useful tools for understanding the roles and function of SSAO, or they may even be valuable substances for treatment of various diseases.
Export Options
About this article
Cite this article as:
Matyus P., Dajka-Halasz B., Foldi A., Haider N., Barlocco D. and Magyar K., Semicarbazide-Sensitive Amine Oxidase: Current Status and Perspectives, Current Medicinal Chemistry 2004; 11 (10) . https://dx.doi.org/10.2174/0929867043365305
DOI https://dx.doi.org/10.2174/0929867043365305 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Leukocytes in Diabetic Retinopathy
Current Diabetes Reviews Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets Adult Stem Cells and the Clinical Arena: Are we Able to Widely Use this Therapy in Patients with Chronic Limbs Arteriopathy and Ischemic Ulcers without Possibility of Revascularization?
Cardiovascular & Hematological Agents in Medicinal Chemistry Progression of Retinopathy in Type 1 Diabetic Women During Pregnancy
Current Diabetes Reviews Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Dogs with Cognitive Dysfunction Syndrome: A Natural Model of Alzheimer’s Disease
Current Alzheimer Research Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage Score For Predicting Outcome
Current Neurovascular Research Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design HDL as a Target for Glycemic Control
Current Drug Targets Activation of Brain Endothelium by Soluble Aggregates of the Amyloid-β Protein Involves Nuclear Factor-κB
Current Alzheimer Research Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction
Current Alzheimer Research Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews C-Peptide and its Correlation to Parameters of Insulin Resistance in the Metabolic Syndrome
CNS & Neurological Disorders - Drug Targets Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment
Current Alzheimer Research